---
schema_version: "secwatch.filing_event.v1"
accession: "0001553350-22-000853"
form_type: "8-K"
ticker: "PDEX"
cik: "0000788920"
company_name: "PRO DEX INC"
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T10:31:24.921307+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Pro-Dex Q1 revenue up 11% to $11.1M; EPS flat at $0.29; gross margin drops 7 pts

## Summary
- Net sales $11.1M (+11% YoY); net income $1.1M ($0.29 diluted EPS) vs $1.1M ($0.28) prior year.
- Gross margin fell to 27% from 34% due to costly handpiece upgrades for largest customer; compensation negotiations ongoing.
- FDA authorized commencement of manufacturing activities at Franklin facility.
- Operating expenses decreased $104K on lower stock compensation and R&D.
- CEO confident negotiations with largest customer will lead to additional revenue.

## SEC filing metadata
- accession: 0001553350-22-000853
- form_type: 8-K
- ticker: PDEX
- cik: 0000788920
- company_name: PRO DEX INC
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/788920/000155335022000853/0001553350-22-000853-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/788920/000155335022000853/pdex_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001553350-22-000853
- JSON: https://secwatch.observer/filing/0001553350-22-000853.json
- Plain text: https://secwatch.observer/filing/0001553350-22-000853.txt

## Key facts
- Earnings Releases
  PRO DEX INC reported fiscal 2023 first quarter ended September 30, 2022 results: revenue $11.1 million, net income $1.1 million, EPS $0.29 per diluted share.
  - Period: fiscal 2023 first quarter ended September 30, 2022
  - Revenue: $11.1 million
  - Net income: $1.1 million
  - EPS: $0.29 per diluted share
  - Result: reported results
  source text: first quarter of fiscal year 2023 with the Securities and Exchange Commission today. Net sales for the three months ended September 30, 2022 increased $1.1 million, or 11%, to $11.1 million from $10.0 million for the three months ended September 30, 2021. The increase is driven primarily by $0.8 million in increased repairs of the surgical handpiece we sell to our
  evidence_url: https://www.sec.gov/Archives/edgar/data/788920/000155335022000853/0001553350-22-000853-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.